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Abstract
Background: Frequent hospitalization and permanent nursing home placement not only affect the well-being of
persons with dementia, but also place great financial strain on society. Therefore, it is important to create effective
strategies to support informal caregivers so that they can continue to perform their demanding role. Preliminary
qualitative evidence suggests that community-based respite services can actually be important for caregivers, and
that the level of evidence should be further established in terms of effectiveness. Therefore, a comparative study to
assess the effectiveness and cost-effectiveness of an in-home respite care program will be initiated.
Methods: This manuscript described a quasi-experimental study to assess (cost)-effectiveness of an in-home respite
care program to support informal caregivers of persons with dementia. Study population: 124 informal caregivers
and persons with dementia will be included in the intervention group and will receive an in-home respite care
program by an organization called Baluchon Alzheimer. 248 dyads will be included in the control group and will
receive standard dementia care. The primary outcome is caregiver burden. Secondary outcomes are: quality of life
of caregivers, frequency of behavioral problems of persons with dementia and the reactions of caregivers to those
problems, intention to institutionalize the care-recipient, time to nursing home placement, resource use of the
care-recipient, and willingness to pay for in-home respite care. When the trial demonstrates a difference in
outcomes between both groups, within-trial and modeled cost-effectiveness analyses will be conducted in
a separate economic evaluation plan to evaluate possible cost-effectiveness of the in-home respite care program
compared to the control group receiving standard dementia care. Finally, the model based cost-effectiveness analyses
will allow to extrapolate effects over a longer time horizon than the duration of the trial.
Discussion: This study will have great added value because to date no studies measured effectiveness and cost-
effectiveness of an in-home respite care program of the Baluchon type. Results of this trial can thus give much more
insight in potential benefits and disadvantages of community-based respite care. Conclusions based on this trial can
help policy-makers in elaborating future directions of dementia care.
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Background
Dementia is a known major public health problem with
serious physical and emotional consequences for pa-
tients and their caregivers, and a high financial strain
upon society. Knowing that on the one hand staying in
the community may result in more quality of life for the
patient and on the other hand there is a high cost of the
disease for the society due to frequent hospitalization
and permanent institutionalization in nursing homes, it
can be stated that informal caregivers are essential in the
care process and probably cost saving for society [1–7].
Although caregiving for a loved one can be very satisfy-
ing, it also demands a lot from informal caregivers over
long periods due to the progressive decline of the disease
[5, 8]. Most research of the past decade has shown that
informal caregivers have more health problems, visit
healthcare professionals more frequently, suffer from iso-
lation, and have an increased risk of depression, distress
and other illness [1, 2, 6, 8–12]. To prevent caregivers
from getting overburdened, different supportive interven-
tions, such as psychoeducation have been developed to
improve their well-being.
Based on a recently conducted systematic review of
comparative studies (randomized controlled trials and
quasi-experimental studies), it was concluded that sup-
porting caregivers is an effective strategy in improving
well-being of caregivers and their recipients resulting in
additional benefits for society. It also appeared that con-
siderable research was done in investigating effectiveness
of psychoeducational interventions, cognitive behavioral
therapy, and occupational therapy, but research on the
comparative effectiveness of respite care - which can be
defined as a supportive service provided in or outside
the home to give the informal caregiver a temporary re-
lieve or beak from caregiving duties - was very rare [13].
An additional review, that also allowed observational
designs without control group, was conducted to investi-
gate the effectiveness of different types of respite care. In
this review it was concluded that day care services are ef-
fective in decreasing caregiver burden and behavioral
problems in people with dementia, but also accelerate time
to nursing home placement. Results of temporary residen-
tial admission were rather mixed and showed unexpected
adverse effects on both caregivers and care-recipients.
No comparable evidence was found for night-time
care in residential settings. Evidence on community-
based respite care, including in-home respite care and
host family respite care, is rare as well. Only one in-
home respite care intervention was identified indicat-
ing some benefits for caregivers. Finally, there was no
research on cost-effectiveness of any of the investi-
gated types of respite care. As a result, the authors
concluded that there is a need for new intervention
studies measuring effectiveness and investigating cost-
effectiveness of respite care. Especially the effect of an
in-home respite program on the caregiver, the care-
recipient, and the healthcare system should be further
investigated [14].
On the other hand, substantial qualitative research in-
dicated high satisfaction and positive perceptions regard-
ing respite care in general and pointed out that breaks
are crucial if caregivers are to continue to keep their
loved ones home. Additionally, many caregivers pointed
out their preference for in-home respite care, especially
because in this way their loved ones can stay in their
trusted environment [14].
Because current evidence suggests that respite services
can actually be important and effective strategies for
caregivers, but that the level of evidence should be fur-
ther established in terms of effectiveness, especially for
in-home respite care, we designed a quasi-experimental
study to assess the effectiveness of an in-home respite
care program compared to a control group not receiving
the same type of in-home respite on the well-being of
the caregiver, the care-recipient, and on the healthcare
system. The latter in terms of resource use, intention to
institutionalize the care-recipient, and time to nursing
home placement.
When the trial demonstrates a difference in out-
comes between both groups within-trial and modeled
cost-effectiveness analyses will be conducted in a sep-
arate economic evaluation plan to evaluate possible
cost-effectiveness of the in-home respite care program
compared to the control group receiving standard demen-
tia care. Finally, the model based cost-effectiveness ana-
lyses will allow to extrapolate effects over a longer time
horizon than the duration of the trial.
The specific research questions to be answered are:
1) Is in-home respite care an effective strategy in
supporting informal caregivers of people with
dementia? Can in-home respite care decrease
their burden, improve their reactions to behavioral
problems and cause a difference in quality of life of
the caregiver?
2) What impact does in-home respite care have on the
frequency of behavioral problems of people with
dementia?
3) What impact does in-home respite care have on the
healthcare system in terms of resource use, intention
to institutionalize, and time to nursing home
admission?
4) Is in-home respite care a cost-effective strategy
in supporting informal caregivers of people with
dementia from the healthcare payer and societal
perspective compared to no in-home respite care?
5) What are informal caregivers of persons with dementia
willing to pay per day for in-home respite care?
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Methods/design
Design
A quasi-experimental study is designed to assess the ef-
fectiveness of an in-home respite care program on care-
givers of persons with dementia. The intervention group
will consist of caregiver/care-recipient dyads receiving
an in-home respite program called “Baluchonnage” and
will be compared to a control group that does not re-
ceive this program. Comparison between the groups will
be done by collecting health related and economic data.
Eventually, if the intervention is effective, modeled and
trial based cost-effectiveness analyses will be undertaken
in a separate economic evaluation plan. Analyses will be
performed from the perspective of the healthcare payer
(RIZIV/INAMI (National Institute for Health and Dis-
ability Insurance) and patient) and from a full societal
viewpoint. Finally, the model based cost-effectiveness
analyses will allow to project effects over a longer time
horizon than the duration of the trial. An additional
five-years’ time-horizon is chosen based on evidence of
the average life expectancy in dementia [15, 16].
Study participants
The study participants are caregiver/care-recipient
dyads. The caregivers must be informal, meaning that
they must not be professional healthcare workers in this
caregiving role. They have to identify themselves as the
main person responsible for the informal care (primary
caregiver). Also, they must speak Dutch or French with
some fluency and be able to read and write. Finally, care-
givers will be excluded if they have cognitive impair-
ments or severe psychiatric comorbidities. The care-
recipient needs to be diagnosed with dementia and must
live in the community. Evidence of symptoms will also
be confirmed by testing for severity (Global Deterior-
ation Scale) [17]. Finally, dyads of the control group
must never had in-home respite of the Baluchon type,
but be eligible and willing to receive it. On the other
hand, dyads from the intervention group who have
already received in-home respite care from the Baluchon
type in the past are still allowed for inclusion in the
intervention group.
The in-home respite intervention
The in-home respite intervention group will receive
in-home respite care also called “Baluchonnage” from
Baluchon Alzheimer Belgium. Baluchon is a non-
profit organization, founded in Québec by gerontolo-
gist Marie Gendron. She responded to the unmet need
of many caregivers willing to take a break from care-
giving duties, but lacking a solution for the person
with dementia allowing them to stay home in their
trusted environment. Eventually from this thought of
mind, “Baluchonnage” was originated making it possible
for those caregivers to take a short break while a trained
support person (also called a “baluchonneuse” or “balu-
chonneur”) takes in their place. During this break,
which can last up to two weeks, the caregiver has time
to rest and return with new energy. For the person with
dementia other resource use, structure, habits, and all
daily activities remain the same. In this way Baluchon
not only addresses to caregiver needs, but also to the
need of the people with dementia feeling best in their
trusted environment [7].
Twenty-four hours before the start of the respite period
the “baluchonneur (se)” arrives at the home of the care-
recipient. This transition period allows the “baluchonneur
(se)” to get to know the environment, get to know the per-
son with dementia and the caregiver, to build a trusting
relationship, and to observe daily habits [7].
Additionally to the provision of respite, “Baluchonnage”
also includes caregiver support by keeping a support diary
during the respite period. In that diary the “baluchonneur
(se)” writes down all daily experiences and strategies on
how to manage the difficult behaviors the caregivers listed
before. This support enables the caregiver to validate
theirs perceptions, to learn how to deal with difficult be-
haviors and to feel understood by somebody. Even after
the end of the respite period the “baluchonneur (se)” re-
mains available for further counsel [7]. In Belgium this
particular type of respite is not subsidized by the National
Health Care Insurance.
Finally, based on ethical considerations, we cannot
prohibit intervention participants from having mul-
tiple Baluchonnage-periods or utilize other standard
dementia care services or supportive services includ-
ing respite care. Especially not since some supportive
respite care services such as: day care, night-time care
(in-home or in a residential setting), and temporary
residential admission are considered standard care in
Belgium. Because use of other services or having mul-
tiple in-home respite periods via Baluchon can poten-
tially influence study results, the extent of use will be
captured with the RUD questionnaire (Resource Use
in Dementia) [18].
The control group - non in-home respite care
The control group receives usual dementia care. This
means that they can have all types of standard dementia
care (including medical, psychological, and other health
and social services) and other supportive initiatives for
informal caregivers including other types of respite care.
As mentioned before, control group dyads who already
utilized in-home respite from Baluchon, which is not
considered standard dementia care in Belgium, will not
be allowed for inclusion. Another reason for exclusion
at baseline is not being eligible or willing to consider
in-home respite via Baluchon.
Vandepitte et al. BMC Geriatrics  (2016) 16:207 Page 3 of 12
Sample size
Sample size calculation was performed using SPSS Sam-
plePower 3®. First, literature was searched to determine
the needed effect size and standard deviation (SD) allow-
ing to distinguish a statistical significant and clinical
relevant difference in the primary outcome, i.e. burden.
Based on the findings of a similar high quality interven-
tion study an effect size of 0.4 was used in the analysis,
which implies a difference of six points on the ZBI scale
(Zarit Burden Interview), and a SD (standard deviation)
of 15 [19]. Also, an average drop-out rate of 20% was
taken into account, a power of 80% and a significance
level at 0.05. Based on these values a total of 124 care-
giver/care-recipient dyads will be needed for the inter-
vention group.
To reduce selection-bias inherent to quasi-experimental
studies an allocation ratio of 1:2 will be used to allow
matching techniques. As a result 248 caregiver/care-
recipient dyads will be needed in the control group.
Recruitment
Participants of the intervention group will be recruited
by Baluchon staff when asking for a first or a new period
of in-home respite care. First, Baluchon staff will de-
scribe the study to the dyads and ask them about their
preparedness to participate. When they give their verbal
consent, contact information will be forwarded to the
research team who will then contact them by phone.
During this call a home visit will be planned to sign the
informed consent and complete the baseline assessment.
In return for their participation, participants will receive
the respite care for free during five days.
Participants for the control group will be recruited by
several general practitioners spread over the different re-
gions in Belgium, by physicians affiliated to the partici-
pating Belgian memory clinics, by several Belgian expert
centers dementia, and by a Belgian sickness fund. Similar
to the recruitment of the intervention group, the phys-
ician will give some information about the study. When
verbal consent to participate is given to the physician,
caregivers will be contacted by phone by the research
team to check eligibility. This will be done by listing dif-
ferent support strategies (including “Baluchonnage”) and
ask the caregiver if they would be interested to receive
this type of support. When caregivers appear to be eli-
gible the research team will plan a home visit to sign the
informed consent and complete the baseline assessment.
Data collection
Data collection of caregiver and care-recipient character-
istics and research outcomes will be conducted at several
assessment moments (Fig. 1). The baseline assessment
will be conducted during a home visit by a member of
the research team. Background characteristics and
baseline values of the research outcomes will be gath-
ered during this assessment. For the intervention group
this will be in the week preceding the respite period. For
the control group this will take place after inclusion.
Two weeks after having the respite period possible
changes in some of the study outcomes will be measured
in the intervention group. Six months after inclusion, at
the primary endpoint of this trial, all research outcomes
(except time to nursing home placement) as well as
some background characteristics (i.e. activities of daily
living, dementia severity, dementia specific medication
use & time spent in caregiving) will be measured again.
Finally, 12 months after the baseline assessment, at second-
ary endpoint, some of the research outcomes will be mea-
sured again as well as time to nursing home placement.
To fulfill the assessments after the baseline assess-
ment, caregivers will be contacted by telephone. This
interviewing technique was chosen because it is the
closest approach to face-to-face-interviewing which is
not achievable in this trial due to time constraints
and practical and organizational limitations. Permis-
sion to use the scales were asked to the authors or to
the organizations responsible for the distribution of a
certain questionnaire. All questionnaires are available
in Dutch and French for use in Belgium. When no
valid translation of a certain questionnaire existed in
Dutch or French for Belgium a forward-back transla-
tion method was performed. In this method three
phases were completed. First, a forward translation
was done. This step was followed by a backward
translation by another independent translator who
had no knowledge or had no contact with the original
questionnaire. During a last reconciliation phase, the
original questionnaire was compared with the back-
ward translation. In this way, discrepancies of transla-
tion were identified and corrected.
Research outcomes and instruments
The trial will evaluate outcomes in the caregiver as well as
in the care recipient (measured via the caregiver) and the
healthcare system (Tables 1 and 2). The primary research
outcome is caregiver burden. Secondary outcomes for
caregivers are: health related quality of life and reactions
to behavioral problems of the care-recipient. A secondary
outcome related to the care-recipient is: frequency of
behavioral problems. Secondary outcomes related to the
healthcare system are: intention to institutionalize the
recipient into a nursing home, and resource use of the
recipient. Finally, in a follow up phase of the trial possible
differences in time to nursing home placement will
be measured (as well as burden and intention to
institutionalize). Additionally, willingness to pay for
“Baluchonnage” per day will be asked to the informal
caregivers (Fig. 1, Tables 1 and 2).
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Caregiver burden
Burden will be measured using the Zarit Burden Inter-
view (ZBI) which is a 22-item validated self-report
questionnaire developed to examine subjective burden
of caregivers of people with dementia. The scale uses a
five point Likert scale – ranged from never to nearly
Fig. 1 timeline of primary and secondary endpoints of the trial
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always present – to score every question. The final score
is ranged between zero (low burden) to 88 (high bur-
den). A validated Dutch and French version for use in
Belgium is available [20, 21].
Health related quality of life of the caregiver
Health related quality of life will be measured using the
EQ-5D-5 L. The EQ-5D-5 L is a valid extension of the
3-level questionnaire. It can be defined as a standardized
non-disease specific value-based instrument to describe
and value health related quality of life. The instrument
consists of five health related domains (mobility, self-
care, daily activities, pain, and depression/anxiety) to
which a score from one to five can be given. Each score
Table 1 Data collection of the intervention group at the
different assessment moments
Intervention
group
Baseline
(T0)
14 days after
intervention
(T1)
T0 + 6
months
(T2)
T0 + 12
months (T3)
Background characteristics
Age CG + CR X
Gender CG + CR X
Region CG + CR X
Etnicity CG + CR X
Marital status CG + CR X
Educational level CG + CR
X
National Registration
Number CR
X
Relationship with CR X
Living situation of CG X
Employment status CG X
Waiting list nursing home
X
Medication use
Dementia-specific CR
X X
Earlier use of Baluchon X
Reason for respite X
Time spent in caregiving X X
Severity of dementia CR X X
ADL functioning CR X X
Research outcomes
Quality of life of CG X X
Burden of CG X X X X
Frequency of behavioral
problems of CR
X X X
Reaction of CG on
behavioral problems
of CR
X X X
Intention to
institutionalize the CR
X X X X
Resource use CR X X
Willingness to pay X
Time to nursing home
placement CR
X
CG Caregiver, CR care-recipient, ADL Activities of Daily Living
Table 2 Data collection of the control group at the different
assessment moments
Control group Baseline
(T0)
14 days after
intervention
(T1)
T0 + 6
months
(T2)
T0 + 12
months (T3)
Background characteristics
Age CG + CR X
Gender CG + CR X
Region CG + CR X
Etnicity CG + CR X
Marital status CG + CR X
Educational level CG + CR
X
National Registration
Number CR
X
Relationship with CR X
Living situation of CG X
Employment status CG X
Waiting list nursing
home CR
X
Medication use
dementia-specific CR
X X
Earlier use of Baluchon X
Preparedness to receive
in-home respite
X
Reason for respite X
Time spent in caregiving X X
Severity of dementia CR X X
ADL functioning CR X X
Research outcomes
Quality of life of CG X X
Burden of CG X X X
Frequency of behavioral
problems of CR
X X
Reaction of CG on
behavioral problems
of CR
X X
Intention to
institutionalize the CR
X X X
Resource use CR X X
Willingness to pay X
Time to nursing home
placement CR
X
CG Caregiver, CR care-recipient, ADL Activities of Daily Living
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indicates the degree of perceived problems with the
domain. Based on this score Quality Adjusted Life Years
(QALYs) can be obtained for the cost-effectiveness
analysis [22, 23]. Validated Dutch and French versions
for Belgium are available as well as a valid telephone
interviewing script in both languages.
Frequency of problematic behaviors and reactions of
caregivers
To measure frequency of problematic behaviors in the
care-recipient and the reaction of caregivers to these
problems, the Revised Memory and Behavior Problems
Checklist (RMBPC) will be used. This validated caregiver
self-report measure contains 24 items including three
domains (depression, memory-related problems and
disruption) and two scales to be answered. One scale
measures the frequency of problem behaviors of the
recipient (five point scale from “never occurs” to “occurs
daily or more often”) and the other measures the reactions
of the caregiver to this behavior (five point scale form “not
at all” to “extremely”). The described forward-back trans-
lation technique was used to translate the original English
questionnaire into Dutch and French for Belgium [17].
Resource use and time spent in caregiving
Resource use of the care-recipient and also time spent in
caregiving will be measured using the Utilization in
Dementia instrument (RUD). This valid, standardized, and
widely used instrument - available in Dutch and French
for Belgium - can be used for collecting data on time spent
in caregiving and resource use of dementia patients and
their caregivers. To collect data on resource use of the
person with dementia, caregivers only have to complete
the part of the questionnaire measuring resource use of
care-recipients [18].
Some small adjustments were made to measure re-
source use in order to better adapt the questionnaire to
the Belgian context and to the setting of this trial. In
contrast to the standard RUD questionnaire, amount of
use of hospital admissions and care in a hospital emer-
gency room will be asked for the last six months
instead of over the last 30 days. Also, we added an add-
itional table to the questionnaire containing the follow-
ing respite services: day care (replaced from another
table), night-time care (community-based or residen-
tial), short-stay, day sitting service, and in-home respite
care (type Baluchon). For these respite services, poten-
tial use in the last six months will be asked. Addition-
ally, a few Dutch words had to be changed to Dutch for
Belgium [18].
Finally, information on potential use of other support
will be collected separately by asking the caregivers if
they currently receive any other supportive initiative for
informal caregivers.
Intention to institutionalize the care-recipient into a
long-term nursing home
The intention to institutionalize the care-recipient will
be assessed using the Desire To Institutionalize scale
(DTI) - originally developed by Morycz in 1985 [24] and
slightly modified for use in the REACH II study [25].
Afterwards this modified version has also been validated
by McCaskill et al. (2011) for use in different ethnical/
racial groups [26]. This questionnaire contains six yes or
no questions each measuring the caregiver’s desire to
institutionalize the recipient into a nursing home, board-
ing home or assisted living. Because for this question-
naire no valid translations were available a forward-back
translation method was used to translate the question-
naire in Dutch and French for Belgium.
Time to nursing home placement
Finally, the time to nursing home placement will be ob-
tained by measuring the interval from the date of study
enrollment to the date of permanent nursing home
placement. Short term admissions in nursing home
placements do not count as definitive nursing home
placement. It is expected that even at 12 months a ma-
jority of patients will not be institutionalized. Hence, this
parameter is to be considered as a secondary endpoint.
Additionally, the National Registration number of
care-recipients will be obtained to allow us to trace
study participants in the IMA database (Intermutualis-
tisch Agentschap) and gather information on their date
of placement in a nursing home over a longer time
period than the trial.
Severity of dementia
Severity of dementia will be collected by using the Global
Deterioration Scale (GDS) which is a valid and reliable in-
strument that distinguishes seven stages of dementia
based on cognitive decline [27]. This questionnaire is not
a neuropsychiatric test, but an instrument to objectively
classify the severity of dementia. It can be adminis-
tered by healthcare professionals and is often used in
scientific research. A Dutch translation was available for
the Netherlands. Two Belgian healthcare professionals
were consulted to check appropriateness of this transla-
tion for the Belgian context. Also a French translation was
made based on the original validated English version using
the forward-back translation technique [28].
ADL functioning
Activities of Daily Living (ADL) of the care-recipient will
be measured using a Belgian adapted version of the Katz
Index of Independence in Activities of Daily Living [29].
The Belgian KATZ scale, which is an official instrument
for mandatory use in Belgium, measures a person’s abil-
ity to perform activities of daily living based on a total
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score on six functions: bathing, dressing, toileting, trans-
ferring, continence, and feeding. Additionally, potential
disorientation in time and place is asked in this ques-
tionnaire. In contrast to the original Katz index devel-
oped by Katz et al. [29] a score between one and four
can be given for each domain of functioning. A score of
four indicates total dependence (or total disorientation),
while a score of one indicates total independence (no
disorientation).
Background characteristics
For caregivers we will obtain the following background
characteristics: age, gender, region, marital status, ethni-
city, educational level, relationship with the care-recipient,
employment status, living situation, and time spent in
caregiving. In both study groups the reason for (potential)
use of respite will be asked based on evidence from the
study of Connell et al. (2012) [30]. Earlier use of Balu-
chonnage will also be questioned to intervention group
participants (Tables 1 and 2).
For the care-recipient the following background char-
acteristics will be collected: age, gender, marital status,
ethnicity, region, National Registration Number, educa-
tional level, being on a waiting list for long-term nursing
home placement, dementia-specific medication use, ac-
tivities of daily living (Belgian Katz scale), and severity of
dementia (GDS). In a later phase, the National Registra-
tion Number of the person with dementia will allow us
to trace study participants in the IMA database (Inter-
mutualistisch Agentschap) and gather information on
resource use and date of placement in a nursing home
over a longer time period than the trial (Tables 1 and 2).
Cost-effectiveness analysis
When appropriate, i.e. if the intervention demonstrates
an effect in the study endpoints, within-trial and mod-
eled cost-effectiveness analyses will be conducted in a
separate economic evaluation plan [31].
First the analysis will be performed from the perspec-
tive of the healthcare payer taking into account direct
healthcare costs for the government’s healthcare budget
(RIZIV/INAMI) as well as patients’ co-payments [32].
Assuming that policy makers would consider reimburse-
ment of in-home respite care of the Baluchon type in the
future, the daily cost of Baluchonnage will be included in
the analyses [33]. Alongside the costs of Baluchonnage
other costs of healthcare resource use including hospital,
residential, and community care will be included [31].
Additionally, also a full societal viewpoint will be
undertaken not only including potential direct health-
care costs for the healthcare budget and patients, but
also all other direct and indirect costs for caregivers and
patients. Because in this viewpoint everyone affected by
the intervention should be considered, caregiver time
and costs (f.e. time spent in caregiving, productivity loss)
as well as resource use and costs of other sectors (f.e.
food delivery) should be included.
Based on the KCE guidelines (Belgian Health Care
Knowledge Centre) for health economic evaluations in
Belgium future costs will be discounted at 3% and future
QALY’s at 1.5% [32]. Health utilities or QALY’s of care-
givers from both intervention arms will be derived from
the Belgian public preference list based on scores on the
EQ-5D [34].
Decision analytic modeling will be carried out to ex-
trapolate effects of the intervention found in the trial to
a longer time horizon. The model will be based on the
results from the trial as well as existing data from litera-
ture. Assumptions, hypotheses, and sources of informa-
tion will be represented in a transparent and clear way.
Finally, the model will be validated by experts.
The incremental cost-effectiveness ratio (ICER) will be
calculated using the following equitation [34]:
ICER ¼ ΔCOSTS difference between mean total cost of intervention group and control groupð Þ
ΔQALYs difference between mean in QALY ’s of intervention group and control groupð Þ
Resource use and costs
As already mentioned, data on resources used by the
care-recipient of each study group will be obtained by
an adapted version of the RUD instrument at baseline
and after six months inclusion [18]. This RUD instru-
ment attempts to include all resource use as defined by
Drummond et al. [31] including: healthcare resource use
containing hospital resources (f.e. in-patient and out-
patient attendances), community care resources (f.e.
general practitioner visits, nurse visits), caregiver and
patient resources (f.e. time spent in caregiver), and re-
source use in other sectors (f.e. social worker visits,
home help visits). Duration and frequency of the used
services will be multiplied by each unit cost of the corre-
sponding service. These unit costs will be obtained from
the Belgian Reimbursement scheme using standard fees
for regularly insured patients and other publicly available
sources [18].
Time spent in caregiving will be calculated at baseline
and after six months using the recall method for which
also a part of the RUD instrument will be utilized.
Next, the amount of time spent in caregiving will be
monetized using the opportunity cost method which
estimates the value of lost informal caregiver benefits
due to spending time on providing informal care [35–37].
Productivity loss of the informal caregiver at productive
age will not be taken into account because this would
cause an overestimation due to double counting [31].
However, for caregivers at productive age we will gather
information on whether their caregiving role effected
their work situation.
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During this trial, dyads of the intervention group will
receive the intervention during five days for free. In nor-
mal circumstances patients must pay 65€ per day, while
350€ per day is covered by charity. However, to measure
the total cost of the in-home respite care service under
investigation in this trial, we will multiply the current
unit cost of Baluchonnage per day (patient + charity) by
the amount of days the in-home respite care was deliv-
ered. Additional costs above the fixed daily tariff - that
patients must normally pay extra - will also be included
such as: travel expenses during the respite period and
having a pet (5€ extra per day) [33].
Additionally, willingness to pay for one day of in-home
respite care by Baluchon will be obtained from both
study groups using the contingent valuation method
(CVM). This method can be defined as a stated prefer-
ence method for eliciting a monetary value to a health-
care program. In this trial we use a closed response
format [35, 36, 38–40].
Finally, for use in the decision analytic model, costs of
nursing home placement will be derived from the aver-
age daily cost for staying in a nursing home in Belgium
at the time of completing secondary endpoint.
Within trial costs
Fixed intervention costs (f.e. program development, staff,
and software) not changing based on the quantity of out-
put, as well as variable costs (f.e. recruitment and assess-
ment costs, intervention costs, and telephone and
postage costs) varying on the quantity of output will be
registered and then calculated into a total cost per care-
giver/recipient dyad. Costs imposed by the study which
are not part of routine practice will not be included in
the cost analysis [31].
Statistical analysis
First of all, descriptive statistics will be represented to draw
a clear profile of the characteristics of study participants.
Therefore the mean, percentages, and the standard devia-
tions of quantitative variables will be displayed. To deter-
mine possible baseline differences between the groups,
mean values of baseline characteristics will be compared
using independent sample t-tests for continuous variables
if normally distributed or by performing Pearson’s chi-
square test for categorical variables. To help control for
bias and confounding, statistical techniques such as pro-
pensity score matching will be used. Propensity score
matching can be seen as a tool to simulate a RCT setting.
In this way we can expect the observed effect to be an
unbiased estimate of the real effect [41, 42].
To investigate possible effects of the intervention on
the primary and secondary outcomes, analysis of vari-
ance will be conducted if the outcome variables are nor-
mally distributed. A P-value of 0.05 will be considered as
significant. All analyses will be based on intention to
treat also taking drop-outs into account and avoiding
overestimation of respite care effects.
When the intervention is effective a cost-effectiveness
analysis in a separate economic evaluation plan will be
performed. ICERs will be calculated for the mean and
upper and lower confidence levels of the costs and con-
sequences. To explore uncertainty one-way-sensitivity
analysis will be conducted around the ICER and illus-
trated in a Tornado diagram. Additionally, on all input
variables a probabilistic sensitivity analysis, also called
Monte Carlo analysis, will be conducted to test robust-
ness of the model. These results will also be illustrated.
Finally, the results and the willingness to pay threshold
of the Belgian Health Care System will be presented in a
cost-effectiveness acceptability curve [34].
To compare time to nursing home placement of per-
sons who use respite care to those who do not, we will
use Kaplan-Meier survival curves to illustrate association
between the comparison groups. By additionally con-
ducting a log-rank test statistical difference between the
groups in time to placement can be found [43].
Ethical issues
The study protocol has been approved by the Ethical
Committee of the University Hospital of Ghent
(B670201526906) prior to the beginning of the recruit-
ment. Additionally, approval was obtained from the
local Ethical Committees affiliated to the participating
memory clinics. Written informed consent will be ob-
tained from all patients before initiation. The study is
registered at ClinicalTrials.gov: NCT02630446.
Discussion
A first major strength of this trial is its contribution to the
need for evidence on effectiveness and cost-effectiveness
of in-home respite care. To date no other studies mea-
sured effectiveness and cost-effectiveness of an in-home
respite service similar to the Baluchon service. Findings of
this trial can also contribute to the elaboration of future
directions of healthcare policies. After all, if in-home res-
pite is effective in supporting informal caregivers and also
cost-effective, policy makers should consider reimburse-
ment of in-home respite care.
This trial has several methodological strengths often
lacking in previous research. First of all, this study only
uses international, validated, and widely used measure-
ment tools to measure the research outcomes. Also, to
better adapt some instruments to the Belgian context
and this trial, adjustments were made for some instru-
ments. When no valid translation in Dutch of French for
Belgium was present we used a proper forward-back
translation technique. Secondly, we performed a sample
size calculation to know the necessary amount of
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caregivers needed to show an effect in the primary out-
come given a certain effect size. In this analysis we also
took into account an average drop-out rate to be expected.
Additionally, intention-to-treat will be used to take into
account drop-outs. To avoid bias and confounding, often
occurring in non-randomized controlled trials, we will use
propensity-score matching to simulate an RCT setting. In
this way, the found intervention effects can be considered
unbiased estimates of the real effect. Finally, active com-
ponents of the intervention are clearly described, reasons
for drop-out will be documented and characteristics of
drop-out participants will be compared to those who
completed the trial.
Despite the promising contribution of this study to
community-based dementia care, several limitations
need to be mentioned as well. First, there is a threat to-
wards internal validity because the used quasi-experimental
study design lacks random assignment of study groups. Al-
though we use inclusion criteria to increase comparability
and statistical efforts such as propensity score matching
will be untaken, there can still be unmeasured confounders
influencing causal inference. Nevertheless, for this particu-
lar research, a quasi-experimental design was preferable
over a randomized controlled trial for feasibility and ethical
reasons. First of all, the limited capacity of Baluchon
Alzheimer Belgium makes it impossible to set up a RCT.
Also, it can be seen as ethically unacceptable to randomly
assign dyads to one of the trials arms. In this way some
caregivers get free respite care while others cannot have
this support during the trial.
Second, we only recruited caregivers asking for in-
home respite care themselves in the intervention group
and caregivers prepared to utilize this service in the con-
trol group. Therefore we cannot speculate whether ef-
fects might be different for caregivers not asking for or
considering this type of support. Also, there is a high
probability that caregiver/care-recipient dyads in the
intervention group with lower socioeconomic status and
lower educational level will be underrepresented because
Baluchonnage is normally a rather expensive service that
is not commonly known in Belgium. Nevertheless, we
will use statistical techniques, such as propensity score
matching, to respond to this problem. Also, the fact that
participants receive the in-home respite care five days
for free can also reduce the gap in socioeconomic status
between intervention en control group.
Another important limitation of this trial is a conse-
quence of not controlling the exact duration of the re-
ceived in-home respite care period in the intervention
group. The latter would not be acceptable due to ethical
considerations and limited capacity of Baluchon Alzheimer
Belgium. Even by setting a minimum duration of five
days as an inclusion criterion, differences in outcome
variables can still be caused by differences in duration.
Nevertheless, to minimalize this phenomenon subgroup
analyses can be undertaken. The same applies for inter-
vention dyads who already received in-home respite in
the past. After all, we can expect that dyads who are
already familiar with in-home respite care react differ-
ently from people who are about to utilize it the first
time. It is known that trust plays a crucial role in
accepting respite care [44, 45]. Finally, use of other sup-
portive strategies such as day care or night-time care
can also influence results for which subgroup analyses
can be undertaken if necessary.
Like other supportive interventions for caregivers this
study only has a rather limited duration and a short follow
up period. A longer time period could produce different
outcomes or show certain effects to be strengthened,
weakened, or sustained over time. Because dementia is a
slow degenerative process, it can be expected that differ-
ences in time to nursing home placement between the
study groups will not be found on such short notice.
Therefore, to allow conclusions about possible difference
in time to placement, we will measure intention to
institutionalize which is seen as an adequate predictor for
real placement into a nursing home [46]. Also, we will ob-
tain the National Registration Number of dementia partic-
ipants allowing to trace information on resource use and
time to nursing home placement over a longer time period
than the trial. Finally, we will perform modeled-based
cost-effectiveness analyses to extrapolate results over a
longer period.
Due to time constraints, organizational limitations,
and high geographical distribution of study participants,
assessments after the first baseline assessment will be
done by telephone interviewing. Although no evidence
was found indicating that the used instruments are not
suited for telephone interviewing and data collection by
telephone is widely performed and well accepted, face-
to-face interviewing still remains the most preferred type
of collecting data.
To measure differences in quality of life of caregivers,
QALYs will be obtained from the EQ-5D. It is known
that this generic preference-based measure of health
lacks sensitivity in determining differences especially in
emotional and mental health problems, and even more
in short periods. Because it is to be expected from this
intervention that in particular those emotional and men-
tal health dimensions will shift, the question can be
asked if the EQ-5D will be sensitive enough to show an
effect on such short notice. Still, its use is preferred over
the use of other disease-specific instruments, which have
proven to be more sensitive, because the developed algo-
rithms to translate the obtained scores into health util-
ities have been subject to a lot of criticism in literature.
Despite the described limitations, inherent to the com-
plex nature of investigating respite care services, this
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study will have great added value because to date no
studies measured effectiveness and cost-effectiveness of
an in-home respite service similar to the Baluchon
service. Results of this trial can give much more insight
in potential benefits and disadvantages of community-
based respite care, especially for informal caregivers and
the healthcare system, but also for care-recipients. Con-
clusions based on this trial can thus help policy-makers
in considering future directions of dementia care.
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